Zydus Lifesciences (ZYDUSLIFE) Q4 02/03 earnings summary

Executive summary

• FY03 consolidated sales rose 29% to Rs 11,286 mn and profit attributable to the group increased 25% to Rs 888 mn; merger-driven expansion makes standalone year-on-year comparisons imperfect.

• Merger, international market entry, cost programs and R&D investment positioned the business for longer-term growth, while higher interest and tax burdens weighed on standalone net margin.

Financial highlights

• Consolidated PBIDT rose 39% to Rs 2,190 mn; PBIDT margin improved to 19.4% from 18% in FY02.

• Merged standalone sales increased 75% to Rs 10,282 mn, PBIDT rose 91% to Rs 1,912 mn, and PAT grew 14% to Rs 766 mn; prior-year figures are not strictly comparable after the merger.

• Standalone PBT rose 44% to Rs 1,053 mn, while interest expense increased to Rs 388 mn from Rs 80 mn and tax provision to Rs 287 mn from Rs 62 mn.

• Consolidated exports were Rs 1,032 mn; export/API mix and merger effects mean reported comparisons with FY02 are not strictly comparable.

Outlook and guidance

• Regulated-market API revenue was expected from FY05 and generic formulation revenue from FY06, supported by US DMF filings and planned ANDA submissions.

• PRISM identified over 1,000 cost-saving opportunities; full profit benefits were expected from FY05 onward. DELTA set a three-year goal to double sales and triple profits.

• Management targeted rapid growth in France by introducing products through Alpharma SAS's registrations and distribution network, with production planned to shift to Moraiya.